Filing Flows › PAVmed (PAVM) › Q2 2026 › vs Q2 2025
PAVmed (PAVM) Q2 2026 vs Q2 2025 (year over year)
PAVmed's revenue rose $27K (+450%) from $6K in Q2 2025 to $33K in Q2 2026.
PAVmed, Q2 2026: revenue $33K (+450% year over year), net loss $6.6M, operating cash flow −$2.7M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $33K | $6K | $27K | +450% |
| Other income, net | $424K | −$7.6M | $8.0M | — |
| Net loss | $6.6M | $12.3M | −$5.7M | -46% |
| Costs & expenses | $7.1M | $12.3M | −$5.3M | -43% |
| Operating costs | $7.1M | $4.7M | $2.3M | +49% |
| Cost of revenue | $122K | $41K | $81K | +198% |
| Research & development | $2.1M | $790K | $1.3M | +162% |
| Sales & marketing | $215K | $220K | −$5K | -2% |
| General & admin | $4.7M | $3.7M | $981K | +27% |
| Operating cash sources | $6.6M | $12.3M | −$5.7M | -46% |
| Depreciation & amortization | $19K | $22K | −$3K | -14% |
| Share-based compensation | $917K | $162K | $755K | +466% |
| Working capital & other | $3.0M | $11.0M | −$8.0M | -73% |
| Cash used in operations | $2.7M | $1.2M | $1.5M | +126% |
| Net loss absorbed | $6.6M | $12.3M | −$5.7M | -46% |
Questions
How much did PAVmed's revenue grow year over year in Q2 2026?
PAVmed's revenue rose $27K (+450%) from $6K in Q2 2025 to $33K in Q2 2026.